儿童原发膜性肾病诊治进展  

Progress in diagnosis and treatment of children with primary membranous nephropathy

作　　者：王芳[1] 王中华 Wang Fang;Wang Zhonghua(Department of Pediatrics,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院儿科,100034

出　　处：《中华实用儿科临床杂志》2020年第17期1310-1312,共3页Chinese Journal of Applied Clinical Pediatrics

摘　　要：膜性肾病(MN)是一种免疫复合物介导的疾病,各年龄均可发病。原发膜性肾病(PMN)在儿童并不常见,但为导致儿童终末期肾病的原因之一。针对M型磷脂酶A2受体和1型血小板反应蛋白7A域的抗体不仅见于成人PMN,亦可见于儿童和青少年PMN,为诊断和监测儿童PMN的有用指标。利妥昔单克隆抗体已成功用于治疗成人PMN,还可能对儿童PMN有效。As an immune complex-mediated renal disease,membranous nephropathy(MN)can occur at all ages.Primary membranous nephropathy(PMN)can lead to end-stage renal disease although it is not common in children.Antibodies against M-type phospholipase A2 receptor/thrombospondin type-1 domain-containing 7A are initially detected in adult PMN,and also present in children and adolescents with PMN.These antibodies serve as useful biomarkers to diagnose and monitor PMN.Rituximab has been successfully used in the treatment of adult PMN,and is possibly effective in children with PMN as well.

关 键 词：儿童 原发膜性肾病 诊断 治疗 

分 类 号：R726.9[医药卫生—儿科]